[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novabridge Biosciences ADR (NBP)

Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 173,474
  • Shares Outstanding, K 115,649
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,270 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75

Options Overview Details

View History
  • Implied Volatility 181.15% (-45.58%)
  • Historical Volatility 57.33%
  • IV Percentile 11%
  • IV Rank 5.14%
  • IV High 1,254.89% on 02/13/26
  • IV Low 122.97% on 12/19/25
  • Expected Move (DTE 25) 0.9520 (63.47%)
  • Put/Call Vol Ratio 2.96
  • Today's Volume 107
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,409
  • Open Int (30-Day) 1,319
  • Expected Range 0.5480 to 2.4520

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 1
  • High Estimate $-0.12
  • Low Estimate $-0.12
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4600 +2.74%
on 06/15/26
1.9450 -22.88%
on 05/26/26
-0.2100 (-12.28%)
since 05/18/26
3-Month
1.4600 +2.74%
on 06/15/26
2.7800 -46.04%
on 04/16/26
-1.3200 (-46.81%)
since 03/18/26
52-Week
1.4600 +2.74%
on 06/15/26
6.7900 -77.91%
on 10/16/25
-0.8300 (-35.62%)
since 06/18/25

Most Recent Stories

More News
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE)...

NBP : 1.5000 (-4.46%)
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.5000 (-4.46%)
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.5000 (-4.46%)
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial...

NBP : 1.5000 (-4.46%)
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data Givastomig, a potential...

NBP : 1.5000 (-4.46%)
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response...

NBP : 1.5000 (-4.46%)
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment...

NBP : 1.5000 (-4.46%)
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD,...

NBP : 1.5000 (-4.46%)
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.5000 (-4.46%)
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around...

NBP : 1.5000 (-4.46%)

Business Summary

NovaBridge Biosciences is a biotechnology platform company committed to accelerating access to innovative medicines. NovaBridge Biosciences, formerly known as I-MAB, is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 1.7333
2nd Resistance Point 1.6767
1st Resistance Point 1.5883
Last Price 1.5000
1st Support Level 1.4433
2nd Support Level 1.3867
3rd Support Level 1.2983

See More

52-Week High 6.7900
Fibonacci 61.8% 4.7539
Fibonacci 50% 4.1250
Fibonacci 38.2% 3.4961
Last Price 1.5000
52-Week Low 1.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.